Stand Up To Cancer and Jazz Pharmaceuticals have entered into a three-year, $4 million research collaboration to research hard-to-treat cancers, including lurbinectedin in pediatric solid tumors and pan-RAF molecules in RAF- and RAS-mutated solid cancers.
The Biden administration has left NIH in a weakened state, intensifying politicization of science on Capitol Hill and eroding the bipartisan support the government’s premier biomedical research agency has traditionally enjoyed.
